AIxplorerBio Closes ￥50 Angel Round of Financing

(VCBeat) Apr. 26, 2021 -- On April 26, 2021, AixPlorerBio, an AI-powered biomedical company, announced the closing of a ￥50 million angel funding round. Established jointly by Dr. Xu Daqiang's team, BioMap and Viva Biotech, AixPlorerBio focuses on the research and development of new drugs in the field of autoimmune systems and neurodegenerative diseases. The company is committed to creating a new mode of new drug R&D based on AI in the process of drug development. The angel round was led by BioMap, with participation from Viva Biotech. As strategic investors, BioMap and Viva Biotech will provide comprehensive support to AixPlorerBio in AI technology, computing capability, underlying multidimensional data, protein structure and new drug development.

AixPlorerBio and BioMap will conduct in-depth cooperation around the joint construction of the AI drug R&D platform and drug pipeline development. BioMap will provide technical support of biological computing engine and high-throughput analysis for AixPlorerBio. AixPlorerBio will take advantage of the drug development and validation technologies for treatments of autoimmune diseases. AixPlorerBio focuses on the areas where there is no effective therapeutic target at present and tries to find new targets by using the immune map of BioMap and its new platform to accelerate drug development.

AixPlorerBio will also take full advantage of Viva Biotech's highly effective drug discovery platform, covering chemical and biosynthesis technologies, and bio-validation technologies, to achieve rapid drug discovery and optimization in the early stage. As the world's leading structure-based drug discovery platform, Viva Biotech has rich experience and technical accumulation in multiple dimensions, such as targeted protein expression and structure study, drug screening, lead compound optimization, etc., which can provide sufficient and efficient data analysis for AixPlorerBio.

BioMap is an AI-driven research and development platform focusing on precision medicine. It is co-founded by Baidu Corporate's founder/CEO Robin Li and former Baidu Ventures' CEO Wei Liu. BioMap strives to accelerate the development of new therapeutics and diagnostic products through the integration of novel AI advancements and frontier biotechnologies.

Viva Biotech's mission is to become a cradle for innovative biotechnology companies from around the world. It has developed a scalable business model combing the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model. Under the CFS model, the Group provides one-stop service for novel drug discovery and production to global pharmaceutical clients. EFS business is dedicated to investing globally in biotech innovation with novel solutions to unmet medical needs across multiple therapeutic areas.